hemophilia

BioMarin, Spark, raising the stakes for hemophilia
BioMarin, Spark, raising the stakes for hemophilia
BioPharma Dive
Biomarin
Spark Therapeutics
hemophilia
BMN 270
SPK-9001
gene therapy
Flag link:
Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab
Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab
Motley Fool
Shire
Roche
hemophilia
emicizumab
Flag link:
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Endpoints
Sanofi
Alnylam
clinical trials
fitusiran
hemophilia
Roche
emicizumab
Flag link:
Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
Endpoints
Pfizer
gene therapy
hemophilia
Sangamo BioSciences
SB-525
hemophilia A
Flag link:
Roche confirms patient death in ACE910 PhIII hemophilia trial, spurring new questions about top blockbuster hopeful
Roche confirms patient death in ACE910 PhIII hemophilia trial, spurring new questions about top blockbuster hopeful
Endpoints
Roche
ACE910
hemophilia
clinical trials
Flag link:
Biogen's hemophilia business spin-off will trade on its own starting Thursday
Biogen's hemophilia business spin-off will trade on its own starting Thursday
Marketwatch
Biogen
spinoffs
Bioverativ
hemophilia
Flag link:
Biogen spinoff begins trading today; New oncology chief at AstraZeneca
Biogen spinoff begins trading today; New oncology chief at AstraZeneca
Endpoints
Biogen
AstraZeneca
oncology
hemophilia
Bioverativ
Flag link:
Spark Gets A Check From Pfizer And A Downgrade From Vetr
Spark Gets A Check From Pfizer And A Downgrade From Vetr
Yahoo/Benzinga
Spark Therapeutics
Pfizer
hemophilia
Flag link:
Coming soon to the Nasdaq: Biogen's hemophilia spinoff
Coming soon to the Nasdaq: Biogen's hemophilia spinoff
Bizjournals.com
Biogen
NASDAQ
Bioverativ
spinoffs
hemophilia
Flag link:
Biogen Approves Spin-out of Hemophilia Business
Biogen Approves Spin-out of Hemophilia Business
TheStreet.com
Biogen
spinoffs
hemophilia
Bioverativ
Flag link:
Alnylam touts hemophilia drug's edge over Roche rival
Alnylam touts hemophilia drug's edge over Roche rival
BioPharma Dive
Alnylam
Roche
hemophilia
fitusiran
Flag link:
Safety issues with Roche drug good for Novo Nordisk
Safety issues with Roche drug good for Novo Nordisk
BioPharma Dive
Roche
Novo Nordisk
ACE910
emicizumab
hemophilia
Flag link:
Shire's new Baxalta hemophilia meds drop the ball in first combined quarter
Shire's new Baxalta hemophilia meds drop the ball in first combined quarter
Fierce Pharma
Shire
Baxalta
hemophilia
earnings
Flag link:
Shire confident in hemophilia despite looming pricing challenge
Shire confident in hemophilia despite looming pricing challenge
BioPharma Dive
Shire
hemophilia
drug pricing
PBMs
Flag link:
Biogen's hemophilia business spinoff planned for early 2017
Biogen's hemophilia business spinoff planned for early 2017
Marketwatch
Biogen
spinoff
hemophilia
Bioverativ
Flag link:
Pfizer Inc, Sanofi SA (ADR) Could Eye Biogen’s Hemophilia Franchise
Pfizer Inc, Sanofi SA (ADR) Could Eye Biogen’s Hemophilia Franchise
Bidness, ETC
Sanofi
Pfizer
Biogen
hemophilia
M&A
Flag link:
Could Shire Fancy Biogen’s Hemophilia Franchise
Could Shire Fancy Biogen’s Hemophilia Franchise
Bidness, ETC
Shire
Biogen M&A
hemophilia
Flag link:
Why Biogen Is Hiving Off Its Hemophilia Business By Investopedia
Why Biogen Is Hiving Off Its Hemophilia Business By Investopedia
Investopedia
Biogen
spinoffs
hemophilia
Flag link:
Biogen’s Hemophilia Spin: Prelude to a Takeover?
Biogen’s Hemophilia Spin: Prelude to a Takeover?
Barron's
Biogen
spinoffs
hemophilia
M&A
Flag link:
Biogen plans to spin off hemophilia drug business into a public company
Biogen plans to spin off hemophilia drug business into a public company
Yahoo/Reuters
Biogen
spinoffs
hemophilia
Flag link: